Mira Pharmaceuticals, Inc. (MIRA) Stock Price & Analysis
Mira Pharmaceuticals, Inc. (MIRA) fell 4.97% to USD 0.88 as of July 25, 2026 at 09:57 UTC, according to Nexqual real-time market data.
MIRA last closed at USD 0.93; the session ranged USD 0.83–0.95 on volume of 87,034 shares. Market capitalization is $37.06M, with a 52-week range of USD 0.83–2.45 (NCM). Source: Nexqual, July 25, 2026 at 09:57 UTC.
Key Statistics (as of July 25, 2026 at 09:57 UTC)
| Price | USD 0.88 |
|---|---|
| Change | ▼ 4.97% (down) |
| Previous Close | USD 0.93 |
| Open | USD 0.95 |
| Day Range | USD 0.83 – 0.95 |
| 52-Week Range | USD 0.83 – 2.45 |
| Volume | 87,034 shares |
| Market Cap | $37.06M |
| Exchange | NCM |
Technical Analysis (MIRA)
Nexqual's technical model rates MIRA "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:57 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.13 (neutral) |
| vs SMA50 | Below (USD 0.97) |
| MACD | -0.02 (negative) |
Analyst Ratings (MIRA)
Wall Street analysts rate MIRA "None", per Nexqual as of July 25, 2026 at 09:57 UTC.
| Consensus Rating | None |
|---|
Earnings (MIRA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.07 vs est -0.08 ▲ beat |
| 2025-06-30 | USD -0.09 vs est -0.13 ▲ beat |
| 2025-03-31 | USD -0.11 vs est -0.15 ▲ beat |
| 2024-12-31 | USD -0.14 vs est -0.24 ▲ beat |
Source: Nexqual, July 25, 2026 at 09:57 UTC.
Financials & Fundamentals (MIRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -184.32% |
| Current Ratio | 82.16 |
| Total Cash | $9.41M |
| Total Debt | $0 |
| Free Cash Flow | $-428,220 |
Source: Nexqual, July 25, 2026 at 09:57 UTC.
Financial Health Score (MIRA)
Nexqual rates Mira Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 09:57 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $9M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$4M |
| Efficiency | Critical — ROE -184%, ROA -112.7% |
Ownership (MIRA)
| Insider Ownership | +16.71% |
|---|---|
| Institutional Ownership | +5.03% |
| Shares Outstanding | 42.02M |
| Float | 35.03M |
| Short % of Float | +0.66% |
Source: Nexqual, July 25, 2026 at 09:57 UTC.
Leadership (MIRA)
Mira Pharmaceuticals, Inc. is led by Erez Aminov (age 46), CEO & Chairman, per Nexqual as of July 25, 2026 at 09:57 UTC.
| CEO & Chairman | Erez Aminov (age 46) |
|---|
Major Backers & Investors (MIRA)
Notable institutional backers of Mira Pharmaceuticals, Inc. include Cross Staff Investments Inc., Fidelity, Suncoast Equity Management, according to Nexqual as of July 25, 2026 at 09:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cross Staff Investments Inc. | 0.86% |
| Fidelity | 0.57% |
| Suncoast Equity Management | 0.22% |
| First American Bank | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.7% |
| Geode Capital | 0.69% |
| BlackRock | 0.27% |
| Northern Trust | 0.16% |
| State Street | 0.12% |
Source: Nexqual, July 25, 2026 at 09:57 UTC.
From Mira Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
- The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.
- It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PBM | Psyence Biomedical Ltd. | USD 2.95 | ▲ 0% |
| BDRX | Biodexa Pharmaceuticals plc | USD 1.65 | ▼ 3.51% |
| TNON | Tenon Medical, Inc. | USD 0.19 | ▼ 3.65% |
| SILO | Silo Pharma, Inc. | USD 4.47 | ▼ 3.04% |
| BBLG | Bone Biologics Corp | USD 1.07 | ▼ 2.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:57 UTC. This page is informational and not investment advice.